Essential thrombocythemia (ET) is a disorder of the bone marrow characterized by an overproduction of platelets (thrombocytes) in the bone marrow. This overproduction of platelets can lead to an increased risk of blood clots and bleeding (hemorrhage). The exact cause of essential thrombocythemia is often not well understood, and it is considered a myeloproliferative neoplasm, a group of disorders where the bone marrow produces too many blood cells.
Dr. Claire Harrison talks about how and when ET is usually diagnosed, expectations for future therapies, recommendations to ET patients, and what it means to live with a rare disease for patients and their relatives.
Dr. Claire Harrison, MD, DM, FRCP, FRCP at the Guy’s and St. Thomas’ NHS Foundation Trust, London, UK
This website uses cookies or similar technologies to be able to offer certain services. All information about the services used can be found in the respective category. In addition to the technically necessary services, you can allow all services, reject all services or make and save your individual settings under “Cookie settings” at any time.
These cookies are necessary for the basic functions of the website.
Required to obtain consent for certain cookies and therefore for the use of certain tools.
If you activate Matomo, we can analyze your use of our website in order to adapt and further improve our services. The following cookies may be set:
Enables the evaluation of visitor information in order to optimize the website and its offer. Learn more about LinkedIn's privacy policy.
If you activate YouTube, videos from this provider will be displayed on our website. The following cookies may be set: